Evidence map›Paper›PMID 40248921›Full record

ReviewCurrent cardiology reviews2025

The Role of Artificial Intelligence in Cardiovascular Disease Risk Prediction: An Updated Review on Current Understanding and Future Research.

Angad Tiwari, Purva C Shah, Harendra Kumar, Tanvi Borse, Anjali Raj Arun, Manognya Chekragari, Sidhant Ochani, Yash R Shah, Adithan Ganesh, Rezwan Ahmed and 2 more

Abstract readReview
In one paragraph

Review in Current cardiology reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Angad TiwariDepartment of Internal Medicine, Maharani Laxmi Bai Medical College, Jhansi, Uttar Pradesh, India.
Purva C ShahDepartment of Internal Medicine, Rochester General Hospital, Rochester, NY 14621, USA.
Harendra KumarDepartment of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Tanvi BorseDepartment of Internal Medicine, Parkview Health, Fort Wayne, ID 46845, USA.
Anjali Raj ArunDepartment of Pediatrics, School of Medicine & Health Sciences, University of North Dakota, Grand Forks, ND 58203, USA.
Manognya ChekragariDepartment of Pediatrics, College of Medicine, University of Florida, Gainesville, FL 32610, USA.
Sidhant OchaniDepartment of Internal Medicine, Khairpur Medical College, Khairpur Mir`s, Pakistan.
Yash R ShahDepartment of Internal Medicine, Trinity Health Oakland, Pontiac, MI 48341, USA.
Adithan GaneshDepartment of Internal Medicine, Icahn School of Medicine, Mount Sinai Elmhurst Hospital Center, Queens, NY 11373, USA.
Rezwan AhmedDepartment of Internal Medicine, Texas A&M School of Medicine, Houston Methodist Hospital, Houston, TX 77030, USA.
Ashish SharmaDepartment of Internal Medicine, University of Connecticut, Farmington, CT 06269, USA.
Maneeth MylavarapuDepartment of Public Health, Adelphi University, NY 11530, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiovascular disease (CVD) Continues to be the leading cause of mortality worldwide, underscoring the critical need for effective prevention and management strategies. The ability to predict cardiovascular risk accurately and cost-effectively is central to improving patient outcomes and reducing the global burden of CVD. While useful, traditional tools used for risk assessment are often limited in their scope and fail to adequately account for atypical presentations and complex patient profiles. These limitations highlight the necessity for more advanced approaches, particularly integrating artificial intelligence (AI) into cardiovascular risk prediction. Our review explores the transformative role of AI in enhancing the accuracy, efficiency, and accessibility of cardiovascular risk prediction models. The implementation of AI-driven risk assessment tools has shown promising results, not only in improving CVD mortality rates but also in enhancing quality of life (QOL) markers and reducing healthcare costs. Machine learning (ML) algorithms predicted 2-year survival rates after MI with improved accuracy compared to traditional models. Deep learning (DL) forecasted hypertension risk with a 91.7% accuracy based on electronic health records. Furthermore, AI-driven ECG (Electrocardiography) analysis has demonstrated high precision in identifying left ventricular systolic dysfunction, even with noisy single-lead data from wearable devices. These tools enable more personalized treatment strategies, foster greater patient engagement, and support informed decision-making by healthcare providers. Unfortunately, the widespread adoption of AI in CVD risk assessment remains a challenge, largely due to a lack of education and acceptance among healthcare professionals. To overcome these barriers, it is crucial to promote broader education on the benefits and applications of AI in cardiovascular risk prediction. By fostering a greater understanding and acceptance of these technologies, we can accelerate their integration into clinical practice, ultimately aiming to mitigate the global impact of CVD.

Indexed as

Artificial IntelligenceCardiovascular DiseasesHeart Disease Risk FactorsHumansQuality of LifeRisk Assessmentadverse cardiac event.artificial intelligenceCardiovascular diseasecomputational intelligencecomputer reasoningmachine intelligence

Identifiers

PMID40248921
PMCPMC12676036

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.